Mesoblast (NASDAQ:MESO) Rating Lowered to Sell at StockNews.com

Mesoblast (NASDAQ:MESO) was downgraded by research analysts at StockNews.com from a “hold” rating to a “sell” rating in a report issued on Wednesday.

Separately, Cantor Fitzgerald restated an “overweight” rating on shares of Mesoblast in a research note on Friday, January 12th. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $13.67.

Mesoblast Stock Down 5.5 %

NASDAQ MESO opened at $7.17 on Wednesday. Mesoblast has a 52 week low of $1.61 and a 52 week high of $10.24. The company has a market capitalization of $818.66 million, a P/E ratio of -6.40 and a beta of 3.45. The stock’s 50-day moving average price is $4.75 and its 200-day moving average price is $3.05.

Institutional Trading of Mesoblast

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Chase Investment Counsel Corp bought a new stake in Mesoblast in the first quarter worth $298,000. Lazari Capital Management Inc. grew its stake in shares of Mesoblast by 9.3% in the 3rd quarter. Lazari Capital Management Inc. now owns 94,034 shares of the company’s stock worth $116,000 after buying an additional 8,000 shares in the last quarter. Finally, Prosperity Wealth Management Inc. bought a new stake in shares of Mesoblast in the 3rd quarter worth about $79,000. Institutional investors own 1.43% of the company’s stock.

Mesoblast Company Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.